Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award
Stephen Dilly Headshot
REDWOOD CITY, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honors an individual who made the greatest contribution to Canada’s innovative healthcare industry the previous year. Dr. Dilly has been recognized for his leadership of Vancouver-headquartered Sierra Oncology, where he led the company through the Phase 3 clinical development of momelotinib and its drive toward commercialization as well as the company’s $1.9 billion acquisition by GSK.
“It is an honor to be named as a finalist for the 2023 Bloom Burton Award. Leading the team at Sierra Oncology to bring momelotinib to the patients who would most benefit was an energizing experience and a highlight of my career. GSK recognized the value of the compound the same way we did and joined forces with us to help accelerate delivery to patients on a global scale,” said Dr. Dilly. “I am incredibly grateful to the physicians and patients who participated in our clinical trials, and the entire team at Sierra who worked diligently to meet demanding timelines throughout the development process. This nomination is a recognition of the work of the entire team and our collective vision to transform promise into patient impact.”
The Bloom Burton Award finalists and winner are chosen by an independent panel of judges consisting of international leaders in healthcare investment, entrepreneurship and journalism. The winner will be announced live at the Bloom Burton Award Gala on September 28, 2023, at the Four Seasons Hotel Toronto. For more information, please visit www.bloomburton.com/gala.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis, and the Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(781) 572-1147
media@codexis.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ae806bb-f003-408b-8f68-d17276433729
